- Report
- January 2022
- 200 Pages
Global
From €7223EUR$7,500USD£6,212GBP
- Report
- August 2022
United States
From €1868EUR$1,940USD£1,607GBP
- Report
- August 2021
Europe
From €3293EUR$3,420USD£2,833GBP
- Report
- August 2021
Global
From €3842EUR$3,990USD£3,305GBP
- Report
- April 2018
Global
From €4334EUR$4,500USD£3,727GBP
- Report
- June 2022
- 120 Pages
Global
From €2408EUR$2,500USD£2,071GBP
- Report
- March 2022
- 120 Pages
Global
From €2408EUR$2,500USD£2,071GBP
- Report
- August 2022
Global
From €953EUR$990USD£820GBP
- Report
- February 2021
Global
From €2850EUR$2,960USD£2,452GBP
- Report
- June 2021
- 43 Pages
Global
From €3847EUR$3,995USD£3,309GBP
- Report
- June 2021
Global
From €10588EUR$10,995USD£9,106GBP
- Report
- March 2020
- 214 Pages
Global
From €3467EUR$3,600USD£2,982GBP
- Report
- March 2020
- 90 Pages
Asia Pacific
From €1445EUR$1,500USD£1,242GBP
- Report
- March 2020
- 90 Pages
Europe
From €1445EUR$1,500USD£1,242GBP
- Report
- March 2020
- 90 Pages
Middle East, Africa
From €1445EUR$1,500USD£1,242GBP
- Report
- March 2020
- 78 Pages
North America
From €1445EUR$1,500USD£1,242GBP
- Report
- July 2023
- 84 Pages
Global
From €3500EUR$3,893USD£3,115GBP
- Report
- May 2023
- 105 Pages
Global
From €3500EUR$3,893USD£3,115GBP
- Report
- June 2022
- 176 Pages
Global
From €1926EUR$2,000USD£1,656GBP
- Drug Pipelines
- September 2020
- 266 Pages
Global
From €1926EUR$2,000USD£1,656GBP
Uveitis is an inflammatory condition of the eye that can cause vision loss and other complications. Immune disorders drugs are used to treat uveitis and other immune-mediated diseases. These drugs are designed to reduce inflammation and suppress the immune system. Commonly used drugs include corticosteroids, immunosuppressants, and biologics. Corticosteroids are used to reduce inflammation and suppress the immune system, while immunosuppressants are used to reduce the activity of the immune system. Biologics are used to target specific parts of the immune system and reduce inflammation.
The uveitis drug market is a rapidly growing segment of the immune disorders drugs market. It is driven by the increasing prevalence of uveitis and other immune-mediated diseases, as well as the development of new drugs and treatments. Companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more